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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is an extremely deadly disease with a 
dismal long-term prognosis. Currently there is an 8% 5-year survival rate for PDAC 
patients, which is due in part to a lack of early detection methods (Siegal et al, 2017). 
Notably, the majority of patients present with late stage disease, when therapeutic 
treatment is not effective. Novel biomarkers that can facilitate early detection of PDAC 
are needed to catch cancer earlier when there are more treatment options. Our laboratory 
has identified an overlooked population of tumor cells in the peripheral blood of cancer 
patients across all stages of disease. These cells are fusion hybrids between macrophages 
and pancreatic tumor cells, and harbor properties of both parental cell types—these cells 
are called circulating hybrid cells (CHCs). CHCs express the epithelial protein 
cytokeratin (CK) and the pan-leukocyte epitope, CD45. We have determined their 
existence in greater numbers compared to conventionally-defined circulating tumor cells 
(CTCs) that express CK, but not CD45 in cancer patients. In addition, we identified 
CHCs in patients with precursor pathologies or precursor lesions across all different 
stages of PDAC, leading us to expect that specific protein expression across the disease 
axis could increase specificity of CHCs in an early detection assay. To support this, I will 
test the hypothesis that distinct protein expression defines different stages of disease in 
the pancreatic cancer continuum. In utilizing a disease-specific tissue microarray, and 
antibodies recognizing discrete proteins identified with immunofluorescence, I 
differentiated states of pancreatic epithelium from normal, pancreatitis, pre-cancer 
(PanIN1, PanIN2, PanIN3), and cancer.  
 
 
 
Introduction 
PDAC is a type of exocrine pancreatic cancer deriving from cells that line ducts in 
the pancreas (Stark, A., & Eibl, G, 2015).  Advanced stages of pancreatic cancer are 
present in around 50% of patients due to the disease’s heterogeneity of genetic mutations 
and lack of distinctive symptoms (Adamska et al, 2017). The only reliably curative 
treatment for patients with pancreatic cancer is surgical resection; however, only pre-
cancerous or early stages of PDAC are considered resectable. In order to detect earlier 
stages of disease efforts must focus on identification of patients with precursors of PDAC 
such as pancreatic intraepithelial neoplasms (PanINs), mucinous cystic neoplasms 
(MCNs), and intraductal mucinous cystic neoplasms (IPMNs). Novel biomarkers are 
needed to detect these precursors, because the most commonly used FDA approved blood 
biomarker test for PDAC, the carbohydrate antigen 19-9 (CA19-9) (Becker et al, 2014), is 
not routinely effective. CA19-9 is a poor screening tool for PDAC as it is expressed in 
low prevalence within the general population and is unreliable as a sensitive readout. 
Another potential biomarker for PDAC are conventionally defined circulating tumor cells 
(CTCs) (Poruk et al, 2016). CTCs are identified in the blood of patients with malignant 
neoplasm, but in very low numbers and rarely in healthy control samples (Poruk et al, 
2016. Therefore, CTC-based assays have failed. 
A novel biomarker, identified in our laboratory, is a circulating tumor cell that is 
the product of tumor cell-macrophage cell fusion, referred to as circulating hybrid cell 
(CHC). These CHCs are of interest due to the discovery of their existence in patients with 
precancerous lesions as well as metastatic pancreatic cancer at levels greater than 
conventionally defined CTCs (Gast et al, 2018). Although CTCs are also found across 
PDAC stages, CHCs exist in numbers greater in magnitude than CTCs in the metastatic 
setting (Gast et al, 2018). Therefore, we hypothesize that distinct protein expression can 
define the various stages of pancreatic ductal adenocarcinoma. 
 Recognizing there are distinct morphologic differences between the different 
stages of pancreatic disease, identification of discrete protein profiles that define each 
stage of cancer can be applied to assays for early detection. Similarly, Schelitter et al 
identified prognostic relationships between histopathology and molecular profile based 
on the morphologic stratification of PDACs through mutational status of the four driver 
genes, KRAS, CDKN2A/p16, SMAD4 and TP53 (Jones et al, 2008). To identify discrete 
disease-specific protein expression, we generated pancreatic tissue microarrays (TMA) 
that represented pathology across the disease continuum (normal, inflammation, PanIN, 
and PDAC). We then validated an extensive number of antibodies with potential 
differential protein expression, and applied these antibodies to the TMA. Utilizing an 
immunofluorescence approach, protein expression patterns were visualized from the 
TMA. Overall, protein expression displayed differential patterns in the epithelium across 
the disease axis. We identified a subset of antibodies that recognized epithelial cells, 
and/or cancer cells and therefore have potential to distinguish different stages of 
pathology across the PDAC disease axis to increase specificity of CHC’s in early 
detection platforms.  
 
 
 
 
 
 
 
 
 
Figure 1: A, B) Human macrophage/tumor fusion: Identification of fusion hybrids in PDAC (left) and 
precancerous neoplasia (PanIN, right). Co-expression of Y-chromosome (red) and tumor epithelial marker 
cytokeratin (gray) demonstrates macrophage/tumor fusion 
C, D) Diagram of macrophage fusion event. Schematic of macrophage fusion with cancer cells to create CHCs 
(C). GFP labeled macrophage fusing with RFP labeled tumor cell resulting in merged phenotype. Fusion event in 
YFP-Macrophages and RFP-Tumor cells (D). E) Cell fusion hybrids (arrowheads) that co-stain for EPCAM 
(yellow) and CD45 (green) and have a Y chromosome (white dot) in their nuclei (blue). Arrows denote 
leukocytes.  
 
Reprinted/adapted from Gast, Charles E., et al. “Cell Fusion Potentiates Tumor Heterogeneity and Reveals 
Circulating Hybrid Cells That Correlate with Stage and Survival.” Science Advances, vol. 4, no. 9, 12 Sept. 2018, 
doi:10.1126/sciadv.aat7828. © The Authors, some rights reserved; exclusive licensee American Association for 
the Advancement of Science. Distributed under a Creative Commons Attribution NonCommercial License 4.0 
(CC BY-NC) http://creativecommons.org/licenses/by-nc/4.0/ 
 
 
 
 
 
 
 
Figure 3: Pancreatic disease morphology (H&E): Healthy to inflamed pancreatic  tissue (A) characterized by 
circular duct structures. Progression through pancreatic intraepithelial neoplasia (PanIN)  and PDAC results in 
increasing ductal irregularity and dysplasia (B,C,D).  
 
Adapted from Clinical Cancer Research, 2000, Volume 6/Issue 8, 2969-2972, Ralph H. Hruban, Michael 
Goggins, Jennifer Parsons, Scott E. Kern, Progression Model for Pancreatic Cancer, with permission from 
AACR. Modifications by Melissa Wong.  
 
A B 
Figure 2: A) Quantification of 
CHCs and CTCs across the 
stages of PDAC development 
through flow cytometry. CHCs 
found in the precancerous setting 
as well as the node -/+ and 
metastatic setting.  
B) Immunofluorescent 
identification of CHCs via the 
co-expression of tumor epithelial 
marker cytokeratin and pan-
leukocyte marker CD45 
(CK+/CD45+, left) and CTCs 
(CK+/CD 45-, right). (Gast, et al, 
2018). 
 
 
Materials and Methods 
Human Subjects/Ethics: 
 Tissue samples were collected with approved protocols according to the ethical 
requirements and regulations of the Oregon Health and Science University (OHSU) 
review board. All patients gave informed consent.  
 
Generation of Tissue Microarray: 
 For tissue preparation, the selected FFPE tissues were marked for the specified 
tissue section utilized for the cores. A template for the TMA production was prepared 
with the tissues organized according to the outline: 
 
 
Figure 4: A) Tissue microarray (TMA) layout. Labels a-f and 0-6 were how we were able to 
designate what specific core/disease stage was being viewed under the microscope (6 cores per 
disease stage and 7 rows in total of the different stages). B) Hematoxylin and Eosin staining of 
TMA. 
 
A 
B 
For standardized sizing of the cores, a donor stylet would be marked at 4.5 mm with 2.5-
3 mm margins on each side of the paraffin block. Utilizing a manual tissue microarrayer, 
the selected punches were mounted and punched about 5mm into a recipient block. The 
blocks were baked in 42 °C for 40 min then cooled for 10 min. The tissue block was cut 
into 4 μM thick sections with a microtome consisting of a blade carrier with an integrated 
transfer bridge, heated water bath, and control unit. Sections were taken from the water 
bath immediately after being stretched out to be placed onto a superfrost glass slide. Once 
the slides are dried in room temperature over night, they are baked in 50 °C between 12-
24 hours. Completed TMA slides were stained according to staining protocol described 
below.  
 
Paraffin Embedded PDAC Tissue IF and Imaging: 
 Tissue samples were preserved by fixing in formalin to preserve the tissue. They 
are then embedded within a paraffin wax block to cut slices (about 10 μM) to mount on a 
microscopic slide. The tissue specimens that are obtained come from sections with PDAC 
present (tumor sections) and sections without (normal sections). The block of human 
tissue are excised from the patient and immersed in a neutral-buffered formalin solution 
for approximately 18-24 hours. In preparation for wax infiltration, the tissue would be 
dehydrated and cleared utilizing increasing concentrates of ethanol to then embed into 
IHC-grade paraffin. Formalin-fixed paraffin embedded (FFPE) specimens with 5 μm 
sections of PDAC on glass slides were also ordered from Knight Biolibrary.  The tissues 
were deparaffinized in three washes of xylene, 30 min, 10 min, and 10 min. Tissue was 
then rehydrated in isopropanol baths, 3x for 3 minutes each, then washed in dH2O for 5 
min, and PBS 3x 3 min. Heat-mediated antigen retrieval was performed in citrate buffer 
(10 mM citric acid at pH 6) at 100 °C for 30 min. Slides were cooled for 25 mins, and 
followed by PBS washes (3x 3 min), and incubation in blocking buffer (5 g BSA, 200 μL 
2.5 M CaCl2, and 500 μL triton x-100) at 20 °C for 30 min. Primary antibodies were 
diluted in blocking buffer; Notch1 (Cell Signaling Technology, 1:100, 1:200, 1:500), 
EpCAM (Biolegend, 1,:100, 1:200, 1:500), Maspin (US Biological, 1:100, 1:200, 1:500), 
CK (ThermoFischer Scientific, 1:20, 1:30, 1:40), MUC4 (Millipore Sigma, 1:100, 1:250, 
1:500), Glypican-1 (ThermoFischer Scientific, 1:50, 1:100, 1:200), BMI1 (Cell Signaling 
Technology, 1:100, 1:200, 1:500), MUC5 (ThermoFischer Scientific, 1:100, 1:200), 
SMAD4 (Abcam, 1:100, 1:200), SerpinB5 (Sigma Aldrich, 1:100, 1:200, 1:500), CXCR4 
(Abcam, 1:100., 1:200, 1:300),  Ras (New East Bio, 1:100, 1:200, 1:500), p53 (Abcam, 
1:100. 1:200, 1:500), p27 (Abcam, 1:100, 1:200, 1:500), S100P (Fischer Scientific, 
1:100, 1:200, 1:300), Erbb2 (Sigma Aldrich, 1:100, 1:200, 1:500), VHL (Abcam, 1:100, 
1:200, 1:500), LHX1 (Origene, 1:100, 1:200, 1:300), IEX1 (ThermoFischer Scientific, 
1:50, 1:100, 1:200), MUC1 (Origene, 1:100, 1:200, 1:500), IMP-3 (Agilent, 1:100, 1:200, 
1:500), Ki67 (Abcam, 1:100, 1:200, 1:500), PhosphoERK (Labome, 1:100, 1:200, 1:500), 
Annexin-A10 (Novus Biologicals, 1:100, 1:200, 1:500). Tissue sections were incubated 
with 100 μL of diluted antibody and were incubated for 12 h at 4 °C. For secondary 
antibody application, tissues were washed with PBS, 3x 3 min, prior to application of 
fluorescent secondary antibodies (1:500 donkey anti-rabbit Alexa Fluor 488, 1:500 goat 
anti mouse AlexaFluor 488, 1:500 donkey anti rabbit Cy3, and 1:500 goat anti mouse 
Cy3; all Jackson ImmunoResearch). Tissue was incubated for 1 h at 20 °C and washed 
with PBS for 3 min before nuclear counterstaining with Hoescht for 10 min. They are 
washed one last time with PBS for 3 min and mounted in n-propyl gallate or prolong 
gold. Fluorescent images were taken utilizing a Zeiss ObserverZ1 microscope.  
 
 
 
Results 
Table 1: Antibody validation results. 
 
 
After validating antibody dilution for optimal tissue staining, the following 
antibodies were initially determined to have potential for staining onto the tissue 
microarray slides: CK (1:40 dilution), EpCAM (1:200 dilution), ECAD (1:200 dilution), 
MUC4 (1:250 dilution), Maspin (1:100 dilution), BMI1 (1:500), Notch1 (1:100 dilition), 
and Glypican-1 (1:100 dilution).  
ECAD has shown to display individualized cellular patterns alongside strong 
membranous expression of tumor and epithelial regions within normal and cancer tissue. 
EpCAM displays membranous and cytoplasmic within tumor regions while also 
expressing within the islets of Langerhans and exocrine glandular cells within normal 
tissue. CK expresses more cytoplasmic in tumor tissue with higher expression in the 
exocrine glandular cells in normal tissue. MUC4 displayed expression localized 
cytoplasmic/membranous in PDAC and did not display in normal tissue. Maspin has 
shown to express more cytoplasmic/membranous within PDAC tissue, yet also has 
instances of expresses nuclear as well. It does not express within the exocrine glandular 
cells in normal tissue. BMI1 expresses nuclear within tumor tissue, and has lower 
expression of the exocrine glandular cells and higher in islets of Langerhans in normal 
tissue. Glypican-1 stains cytoplasmic/membranous in PDAC tissue with no expression in 
normal tissue. Although Notch1 was of initial interest to apply onto a TMA, it did not 
give discrete protein profile expression.  
Antibody staining of TMA:  
Currently, MUC4 and ECAD have displayed differentiated expression throughout 
PDAC on the TMA slides. MUC4 has expressed throughout the pancreatic disease states, 
yet did not display in the Normal or Pancreatitis tissue cores. This indicates MUC4 as a 
precursor before differentiated PDAC. As for ECAD, it has shown expression throughout 
the disease states, with prominence of immunofluorescence in the advanced stages. 
Because of these antibody’s discrete expression throughout the pancreatic cancer, these 
were the ones that have been captured so far utilizing digital microscopy. There has been 
some variance in the antigen retrieval step for the IHC protocol within certain antibodies, 
which needs to be solidified before applying the rest onto TMAs. In order to do so, 
different timings of antigen retrievals have been tested and will be continued alongside 
varying methods of the retrieval if time adjustments are deemed unnecessary.  
 
 
 
Immunohistochemistry Staining of Paraffin Embedded Formalin Fixed Pancreatic 
Normal and PDAC Tissue 
 
 
 
Figure 5: Preliminary staining across PDAC Continuum: Left is the normal tissue while right is PDAC 
tissue. These tissues have been costained with their respective protein markers and DAPI, which is a 
nuclear stain. EpCAM staining in PDAC remains specifically around the epithelium, which is also 
evident in H&E staining (top left of PDAC). Maspin stains cytoplasmic/membranous and secretes into 
extracellular space in PDAC tissue, yet is not present in normal tissue. Notch1 appears to stain more 
nuclear in PDAC, and more apical cytoplasm and membranous in normal tissue. ECAD stains in both 
PDAC and normal tissue with individualized cellular expression on the cell surface. 
 
Immunohistochemistry Staining of Paraffin Embedded Formalin Fixed Pancreatic Tissue 
Micro Array 
 
 
 
Figure 6: IHC staining on Tissue Micro Array: 
Stained with MUC4. Expression was seen 
across disease stages with no expression within 
Normal or Pancreatitis cores. This indicates 
MUC4 as a precursor before differentiated 
PDAC. 
 
 
 
 
 
Figure 7: IHC staining on Tissue Micro Array: 
Stained with ECAD. Expression was seen across 
disease stages with continuous expressions 
throughout PDAC.  
Discussion 
Because PDAC is such an aggressive disease, gaining the ability to detect earlier 
stages is critical. Currently, early detection methods are dismal and early pancreatic 
cancers do not often cause any symptoms (Ryan et al, 2014). However, protein 
expression can change over progressive disease states. Identification of the 
morphological differences within disease stages alongside protein expression can help 
facilitate early detection.  
Protein expression results have indicated increased expression of proteins such as 
MUC4, Bmi1, CD133, and CD166 throughout PDAC progression. These staining 
patterns varied across the phases of PanIN and thus display complex regulation of the 
epithelium across the disease axis. In this study, various antibodies were tested on PDAC 
tissue as well as normal tissue. Through IHC methods, we identified a subset of 
antibodies that displayed expression differences between PDAC tissue and normal tissue. 
For specific epithelial expression, ECAD, EpCAM, and CK were highly and uniformly 
expressed in all epithelia. For cancer specific protein expression, Maspin, BMI1, and 
Glypican-1 displayed strong expression. These antibodies have showcased specificities in 
their expression patterns between PDAC and normal tissue, thus the process of applying 
them to TMA slides have begun.  
ECAD was selected for the panel due to findings that loss of ECAD can generate 
dedifferentiation of human carcinoma cells, thus being a tumor suppressor gene (Frixen, 
1991). It has shown to express in pancreatic carcinoma cell lines. ECAD is an important 
molecule for cell-cell adhesion in epithelial tissues localizing on surfaces of epithelial 
cells within adheren junctions (Pećina-Slause, 2003), so it would be expected to see 
expression from normal tissue and throughout the stages of PDAC. EpCAM is an 
epithelial cell adhesion molecule that has also shown prominent expression within cancer 
stem cells (CSC) with frequent expression in various cancers, including pancreatic cancer 
(Gires et al, 2009). Cell adhesion is a regulator of cell polarity, thus affecting 
proliferation and differentiation for contact inhibition (Schnell et al, 2013). In also being 
an epithelial cell adhesion molecule, it is expected to be present in normal tissue to 
PDAC tissue. CK has been found to be abundant in epithelial cells alongside being useful 
markers for epithelial malignancies (Barak et al, 2004). There has been more than 20 
cytokeratins identified through releasing from proliferating or apoptotic cells, which 
makes CK another marker found in normal tissue and earlier stages of pancreatic cancer 
(Barak et al, 2004). Maspin is a serine protease inhibitor that has displayed evidence of 
limiting metastases in various carcinomas, alongside expression in pancreatic cancer and 
not in normal pancreatic tissue (Nash et al, 2007). Because tumor metastasis requires 
invasion of tumor cells, increased adhesion through Maspin can be a contributor to 
inhibiting tumor metastases and displaying expression in late stages PanIn and PDAC 
(Berardi et al, 2013).  BMI1 is a part of the polycomb protein family and controls histone 
ubiquitination and repression of genomic loci. It has shown upregulation in early PanINs 
(Schofield et al, 2015), and should be expected to be expressed throughout all stages of 
pancreatic cancer. Since BMI1 represses genes that induce cell death and senescence, it is 
required for maintaining adult stem cells in some tissues (Park et al, 2004). Lastly, 
Glypican-1 is a protein anchored to the cell membrane that has shown overexpression 
within pancreatic cancer (Melo et al, 2015). They are a member of heparan sulfate 
proteoglycans, which are abundant on cell surfaces, extracellular matrices, and 
connective tissues alongside being involved in cell recognition, growth, adhesion, 
proliferation, differentiation, and morphogenesis (Frampton et al, 2018). Because of these 
findings, alongside preliminary staining, all of these markers were selected to be applied 
onto TMA. 
Overall, healthy and PDAC regions are the only tissues that could be clearly 
identified on the basis of epithelial and CSC markers. In order to observe a more stage 
specific molecular signature, more PanIN specific markers must be targeted. Future plans 
at this point once classifying appropriate antibody expression in PDAC, are to continue 
utilizing the antibodies chosen for an Epithelial (ECAD, EpCAM, CK) and Cancer 
(Maspin, BMI1, Glypican-1) to be placed on tissue micro arrays as cocktails. By utilizing 
a disease-specific tissue microarray alongside protein markers based upon 
immunofluorescence, we are continuing to differentiate states of pancreatic epithelium 
from normal, pancreatitis, pre-cancer (PanIN1, PanIN2, PanIN3), and cancer.  
In differentiating states of pancreatic epithelium, the antibody panels can be 
applied to patient CHCs. By quantifying CHCs and identifying a correlation between the 
prominence of CHCs, immunofluorescent expression, and disease stage, we can 
eventually create a more specific biomarker for pancreatic cancer detection. PDAC is one 
of the most lethal cancers with few treatments for patients, thus being the fourth common 
cause of cancer related deaths (Becker et al, 2014). 80-90% present late stages of the 
disease that are surgically incurable (Stark et al, 2015). Only precancerous or early stage 
PDAC is considered surgically resectable (Becker et al, 2014), so the focus should be on 
improving methods for early detection – earlier stages are usually asymptomatic (Becker 
et al, 2014). By identifying and screening high-risk populations before their symptoms 
arise, detection of earlier-stage lesions that may still be at a surgically-resectable stage 
can increase survival rates. In working to discover an early detection method involving 
the analysis of patient blood, a more non-invasive method can be created and utilized to 
determine the status of disease at much earlier states.  
 
 
 
Abbreviations 
• PDAC: Pancreatic ductal adenocarcinoma 
• PanIN: Pancreatic intraepithelial neoplasm 
• IPMN: Intraductal mucinous cystic neoplasm 
• MCN: Mucinous cystic neoplasm 
• CHC: Circulating hybrid cell 
• CTC: Circulating tumor tell 
• CSC: Cancer stem cell 
• TMA: Tissue microarray 
• IHC: Immunohistochemistry  
• IF: Immunofluorescence  
• FFPE: Formalin-fixed paraffin embedded  
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